Lupin selects Hewlett Packard Enterprise to accelerate innovation, optimise cloud costs

IMT News Desk
IMT News Desk
· 2 min read

HPE Private Cloud Enterprise will enhance scalability and operational performance for Lupin

Hewlett Packard Enterprise announced that Mumbai-based Lupin has selected HPE Private Cloud Enterprise for a fully managed turnkey solution that modernises its private cloud infrastructure to accelerate innovation and enables them to seamlessly repatriate workloads from the public cloud. It reinforces HPE’s leadership in private cloud adoption and its commitment to empowering enterprises with cloud-native solutions.

Lupin, an existing HPE GreenLake cloud customer, has selected the HPE Private Cloud Enterprise solution to reduce its overall IT expenditure without compromising on the cloud experience. The integration of HPE’s solution will enable data sovereignty, operational efficiency, faster innovation, and energy efficiency.

HPE Managed Services will not only oversee SAP S/4 HANA instances running on HPE systems but also manage the network and security setup in data centers for Lupin.

HPE Private Cloud Enterprise is perfectly aligned with our business objectives, offering the flexibility, security, and efficiency needed to facilitate our growth and consistently provide high-quality products to our customers,” said Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU, Lupin. “It signifies a strategic move that promises efficiency and cost savings.”

“Our partnership with Lupin reinforces our innovation and commitment to remaining the leader in hybrid and private cloud solutions. It demonstrates the value of our efforts and the trust our clients place in us,” said Som Satsangi, SVP and managing director, HPE India. “This collaboration underscores HPE’s commitment to enabling enterprises with cutting-edge cloud solutions that drive business success. As more organizations in India embrace private cloud for its security, control, and efficiency, HPE remains at the forefront of this digital shift.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk